Literature DB >> 16132992

[Asymptomatic concentric visual field deficits and optic nerve atrophy].

S Mennel1, S Schulze, C H Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16132992     DOI： 10.1007/s00347-005-1263-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  10 in total

1.  The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.

Authors:  P Hardus; W M Verduin; T T Berendschot; M Kamermans; G Postma; J S Stilma; C W van Veelen
Journal:  Acta Ophthalmol Scand       Date:  2001-04

2.  No reversion in vigabatrin-associated visual field defects.

Authors:  I Nousiainen; M Mäntyjärvi; R Kälviäinen
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

3.  Vigabatrin visual toxicity: evolution and dose dependence.

Authors:  K Malmgren; E Ben-Menachem; L Frisén
Journal:  Epilepsia       Date:  2001-05       Impact factor: 5.864

4.  Vigabatrin: longterm follow-up of electrophysiology and visual field examinations.

Authors:  Peter Hardus; Willem Verduin; Tos Berendschot; Gina Postma; Jan Stilma; Cees van Veelen
Journal:  Acta Ophthalmol Scand       Date:  2003-10

5.  Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.

Authors:  G F Harding
Journal:  BMJ       Date:  1997-06-07

6.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

7.  Visual field loss associated with vigabatrin: quantification and relation to dosage.

Authors:  P Hardus; W M Verduin; M Engelsman; P M Edelbroek; J P Segers; T T Berendschot; J S Stilma
Journal:  Epilepsia       Date:  2001-02       Impact factor: 5.864

8.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

9.  Visual function loss from vigabatrin: effect of stopping the drug.

Authors:  M A Johnson; G L Krauss; N R Miller; M Medura; S R Paul
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

10.  [Vigabatrin-associated bilateral simple optic nerve atrophy with visual field constriction. A case report and a survey of the literature].

Authors:  Arne Viestenz; Anja Viestenz; C Y Mardin
Journal:  Ophthalmologe       Date:  2003-05       Impact factor: 1.059
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.